You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Polyionic Papillomavirus like Particles VLP for the Treatment of HPV oropharyngeal squamous cell carcinomas OPCs

    SBC: PATHOVAX, LLC            Topic: 102

    The broader impact commercial potential of PathoVax s STTR phase I proposal is to improve outcomes of cancer immuno therapy utilizing a vaccine formulation combining an immunogenic chimeric virus like particle cVLP vaccine with FDA approved immune check point inhibitors PathoVax proposes to develop this technology for treatment of human papillomavirus HPV associated cancers However cancer ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Virtual reality games to assess and habilitate auditory spatial awareness

    SBC: VisiSonics Corporation            Topic: NIDCD

    Project Summary Virtual reality games to assess and habilitate auditory spatial awareness Auditory spatial awareness ASA is the critically important skill of using sound to understand extrapersonal space and its content Both explicit sound localization and implicit environmental awareness aspects of ASA contribute to everyday listening effort fatigue and spatial attention Because heari ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Trans‐nasal delivery of chemotherapy to glioblastoma using magnetic nanoparticles and magnetic focusing

    SBC: Weinberg Medical Physics, Inc.            Topic: 102

    Abstract Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has only extended survival to approximately to years Preliminary pre clinical findings suggest the potential effectiveness of the candidate drug cyclopamine However the drug is toxic to ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Assessing Skills and Treatment Progress in Basic Communicators of All Ages The Basic Social and Communication Behavior Scales BSCBS Phase I

    SBC: PAUL H BROOKES PUBLISHING CO., INC.            Topic: NIDCD

    Project Summary Abstract Effective communication intervention depends on reliable tools for identifying communication concerns and tracking changes in skills Established tools for detecting and tracking skills in early intentional communicators i e directing a behavior such as reaching toward an adult to convey a message involve communication temptations and assessing a wide variety of child ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. In Vivo Editing for Hemophilia Gene Therapy

    SBC: GENVEC, INC.            Topic: 100

    Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government